These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 31532789)
21. Phase 4 randomized trial of intradermal low-antigen-content inactivated influenza vaccine versus standard-dose intramuscular vaccine in HIV-1-infected adults. Ansaldi F; Valle L; de Florentiis D; Parodi V; Murdaca G; Bruzzone B; Durando P; Setti M; Icardi G Hum Vaccin Immunother; 2012 Aug; 8(8):1048-52. PubMed ID: 22832261 [TBL] [Abstract][Full Text] [Related]
22. Randomized Controlled Trial to Compare Immunogenicity of Standard-Dose Intramuscular Versus Intradermal Trivalent Inactivated Influenza Vaccine in HIV-Infected Men Who Have Sex With Men in Bangkok, Thailand. Garg S; Thongcharoen P; Praphasiri P; Chitwarakorn A; Sathirapanya P; Fernandez S; Rungrojcharoenkit K; Chonwattana W; Mock PA; Sukwicha W; Katz JM; Widdowson MA; Curlin ME; Gibbons RV; Holtz TH; Dawood FS; Olsen SJ Clin Infect Dis; 2016 Feb; 62(3):383-391. PubMed ID: 26486702 [TBL] [Abstract][Full Text] [Related]
23. Assessment of an optimized manufacturing process for inactivated quadrivalent influenza vaccine: a phase III, randomized, double-blind, safety and immunogenicity study in children and adults. Claeys C; Drame M; García-Sicilia J; Zaman K; Carmona A; Tran PM; Miranda M; Martinón-Torres F; Thollot F; Horn M; Schwarz TF; Behre U; Merino JM; Sadowska-Krawczenko I; Szymański H; Schu P; Neumeier E; Li P; Jain VK; Innis BL BMC Infect Dis; 2018 Apr; 18(1):186. PubMed ID: 29669531 [TBL] [Abstract][Full Text] [Related]
24. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. DiazGranados CA; Dunning AJ; Kimmel M; Kirby D; Treanor J; Collins A; Pollak R; Christoff J; Earl J; Landolfi V; Martin E; Gurunathan S; Nathan R; Greenberg DP; Tornieporth NG; Decker MD; Talbot HK N Engl J Med; 2014 Aug; 371(7):635-45. PubMed ID: 25119609 [TBL] [Abstract][Full Text] [Related]
25. Intradermal influenza vaccination of healthy adults using a new microinjection system: a 3-year randomised controlled safety and immunogenicity trial. Beran J; Ambrozaitis A; Laiskonis A; Mickuviene N; Bacart P; Calozet Y; Demanet E; Heijmans S; Van Belle P; Weber F; Salamand C BMC Med; 2009 Apr; 7():13. PubMed ID: 19341446 [TBL] [Abstract][Full Text] [Related]
26. Intradermally-administered influenza virus vaccine is safe and immunogenic in healthy adults 18-64 years of age. Gorse GJ; Falsey AR; Fling JA; Poling TL; Strout CB; Tsang PH Vaccine; 2013 May; 31(19):2358-65. PubMed ID: 23499604 [TBL] [Abstract][Full Text] [Related]
27. Randomized safety and immunogenicity trial of a seasonal trivalent inactivated split virion influenza vaccine (IVACFLU-S) in healthy young Vietnamese adults. Anh DD; Thiem VD; Anh NTH; Huong VM; Nga NT; Thang TC; Thai DH; Chien VC; Holt R; Wahid R; Flores J; Berlanda Scorza F; Taylor DN Vaccine; 2016 Oct; 34(45):5457-5462. PubMed ID: 27567493 [TBL] [Abstract][Full Text] [Related]
28. Immune responses to intradermal and intramuscular inactivated influenza vaccine among older age group. Boonnak K; Dhitavat J; Thantamnu N; Kosoltanapiwat N; Auayporn M; Jiang L; Puthavathana P; Pitisuttithum P Vaccine; 2017 Dec; 35(52):7339-7346. PubMed ID: 29157960 [TBL] [Abstract][Full Text] [Related]
29. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. Holland D; Booy R; De Looze F; Eizenberg P; McDonald J; Karrasch J; McKeirnan M; Salem H; Mills G; Reid J; Weber F; Saville M J Infect Dis; 2008 Sep; 198(5):650-8. PubMed ID: 18652550 [TBL] [Abstract][Full Text] [Related]
30. Enhanced passive safety surveillance of three marketed influenza vaccines in the UK and the Republic of Ireland during the 2017/18 season. Gandhi-Banga S; Chabanon AL; Eymin C; Caroe T; Butler K; Moureau A Hum Vaccin Immunother; 2019; 15(9):2154-2158. PubMed ID: 30897026 [TBL] [Abstract][Full Text] [Related]
31. A dose-ranging study in older adults to compare the safety and immunogenicity profiles of MF59®-adjuvanted and non-adjuvanted seasonal influenza vaccines following intradermal and intramuscular administration. Della Cioppa G; Nicolay U; Lindert K; Leroux-Roels G; Clement F; Castellino F; Galli C; Groth N; Levin Y; Del Giudice G Hum Vaccin Immunother; 2014; 10(6):1701-10. PubMed ID: 24732325 [TBL] [Abstract][Full Text] [Related]
32. Immunogenicity and safety of the Southern Hemisphere 2015 formulation of Vaxigrip®. Latreille-Barbier M; Rouzier R; Astruc B; Lavis N; Donazzolo Y Hum Vaccin Immunother; 2017 Nov; 13(11):2674-2677. PubMed ID: 28937844 [TBL] [Abstract][Full Text] [Related]
33. Safety and immunogenicity of revaccination with reduced dose intradermal and standard dose intramuscular influenza vaccines in adults 18-64 years of age. Gorse GJ; Falsey AR; Johnson CM; Morrison D; Fried DL; Ervin JE; Greenberg DP; Ozol-Godfrey A; Landolfi V; Tsang PH Vaccine; 2013 Dec; 31(50):6034-40. PubMed ID: 24055306 [TBL] [Abstract][Full Text] [Related]
34. Safety and immunogenicity of an intramuscular quadrivalent influenza vaccine in children 3 to 8 y of age: A phase III randomized controlled study. Pepin S; Szymanski H; Rochín Kobashi IA; Villagomez Martinez S; González Zamora JF; Brzostek J; Huang LM; Chiu CH; Chen PY; Ahonen A; Forstén A; Seppä I; Quiroz RF; Korhonen T; Rivas E; Monfredo C; Hutagalung Y; Menezes J; Vesikari T Hum Vaccin Immunother; 2016 Dec; 12(12):3072-3078. PubMed ID: 27565435 [TBL] [Abstract][Full Text] [Related]
35. Immunogenicity and safety of intradermal influenza vaccination in healthy older adults. Chi RC; Rock MT; Neuzil KM Clin Infect Dis; 2010 May; 50(10):1331-8. PubMed ID: 20377407 [TBL] [Abstract][Full Text] [Related]
36. Immunogenicity and safety of a split-virion quadrivalent influenza vaccine in adults 18-60 years of age in the Republic of Korea. Choi WS; Noh JY; Lee J; Choi JY; Lee JS; Kim MS; Kim HS; Bang J; Lavis N; Kim WJ Hum Vaccin Immunother; 2018 Mar; 14(3):587-592. PubMed ID: 28933625 [TBL] [Abstract][Full Text] [Related]
37. DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials. Ledgerwood JE; Wei CJ; Hu Z; Gordon IJ; Enama ME; Hendel CS; McTamney PM; Pearce MB; Yassine HM; Boyington JC; Bailer R; Tumpey TM; Koup RA; Mascola JR; Nabel GJ; Graham BS; Lancet Infect Dis; 2011 Dec; 11(12):916-24. PubMed ID: 21975270 [TBL] [Abstract][Full Text] [Related]
38. Safety, tolerability, acceptability and immunogenicity of an influenza vaccine delivered to human skin by a novel high-density microprojection array patch (Nanopatch™). Fernando GJP; Hickling J; Jayashi Flores CM; Griffin P; Anderson CD; Skinner SR; Davies C; Witham K; Pryor M; Bodle J; Rockman S; Frazer IH; Forster AH Vaccine; 2018 Jun; 36(26):3779-3788. PubMed ID: 29779922 [TBL] [Abstract][Full Text] [Related]
39. A new approach to estimate vaccine efficacy based on immunogenicity data applied to influenza vaccines administered by the intradermal or intramuscular routes. Coudeville L; Andre P; Bailleux F; Weber F; Plotkin S Hum Vaccin; 2010 Oct; 6(10):841-8. PubMed ID: 20930559 [TBL] [Abstract][Full Text] [Related]
40. Phase 1 study of pandemic H1 DNA vaccine in healthy adults. Crank MC; Gordon IJ; Yamshchikov GV; Sitar S; Hu Z; Enama ME; Holman LA; Bailer RT; Pearce MB; Koup RA; Mascola JR; Nabel GJ; Tumpey TM; Schwartz RM; Graham BS; Ledgerwood JE; PLoS One; 2015; 10(4):e0123969. PubMed ID: 25884189 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]